SCHEMBL4866812

SCHEMBL4866812

CCSc1nc(NCCOCCO)c2ccccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
LATS1 O95835 1/20 0.45
TSHR P16473 1/20 0.44
MAPK1 P28482 2/20 0.44
GBA1 P04062 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RECQL P46063 1/20 0.44
KCNH3 Q9ULD8 1/20 0.43
LMNA P02545 1/20 0.43
RAD52 P43351 1/20 0.43
MERTK Q12866 1/20 0.43
APP P05067 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865325 0.87 MAPK1 (0.57) MAPTTSHRMAPK1GBA1KDM4E
SCHEMBL4867969 0.85 MAPT (0.59) MAPTTSHRMAPK1KDM4EALDH1A1
SCHEMBL4859009 0.81 LATS1 (0.49) MAPTLATS1TSHRMAPK1GBA1
SCHEMBL4867045 0.80 ACP1 (0.63) MAPTMAPK1GBA1KDM4EALDH1A1
SCHEMBL4864553 0.79 LMNA (0.65) MAPTMAPK1KDM4EKMT2ALMNA
SCHEMBL8898682 0.79 APP (0.60) MAPTLATS1MAPK1GBA1KDM4E
SCHEMBL4866537 0.78 TSHR (0.49) MAPTLATS1TSHRMAPK1GBA1
SCHEMBL4938097 0.78 TLR7 (0.51) MAPTLATS1TSHRMAPK1GBA1
SCHEMBL4863789 0.78 GBA1 (0.65) MAPTTSHRMAPK1GBA1KDM4E
SCHEMBL4864697 0.78 MAPK1 (0.73) MAPTLATS1TSHRMAPK1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPT 4050/4885LATS1 4035/4885TSHR 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.